Thrivent Financial for Lutherans Buys Shares of 199,467 Teva Pharmaceutical Industries Ltd. $TEVA

Thrivent Financial for Lutherans purchased a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 199,467 shares of the company’s stock, valued at approximately $4,029,000.

A number of other large investors also recently modified their holdings of TEVA. National Pension Service raised its stake in shares of Teva Pharmaceutical Industries by 24.2% during the third quarter. National Pension Service now owns 2,073,293 shares of the company’s stock valued at $41,881,000 after purchasing an additional 404,526 shares in the last quarter. LRI Investments LLC increased its stake in Teva Pharmaceutical Industries by 246.0% during the 3rd quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock valued at $57,000 after buying an additional 2,000 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Teva Pharmaceutical Industries by 40.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,707 shares of the company’s stock worth $156,000 after buying an additional 2,233 shares in the last quarter. Retirement Planning Co of New England Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 1.8% in the 3rd quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company’s stock worth $671,000 after acquiring an additional 588 shares during the period. Finally, Genesee Capital Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 22.4% in the 3rd quarter. Genesee Capital Advisors LLC now owns 16,364 shares of the company’s stock worth $331,000 after acquiring an additional 3,000 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. The Goldman Sachs Group boosted their target price on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Jefferies Financial Group boosted their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Truist Financial upped their price objective on Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, December 22nd. Finally, Scotiabank boosted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $36.00.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 216,892 shares of the business’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the sale, the insider directly owned 52,828 shares of the company’s stock, valued at $1,517,748.44. The trade was a 80.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Amir Weiss sold 12,300 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the completion of the sale, the chief accounting officer owned 5,650 shares of the company’s stock, valued at $170,630. The trade was a 68.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 422,060 shares of company stock valued at $12,254,965. 0.49% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Trading Down 0.3%

Shares of NYSE TEVA opened at $34.69 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $37.35. The company has a market cap of $39.79 billion, a price-to-earnings ratio of 28.91, a P/E/G ratio of 1.98 and a beta of 0.70. The business has a fifty day simple moving average of $31.43 and a 200-day simple moving average of $23.87.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter in the previous year, the company earned $0.71 EPS. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.